ImmunityBio Stock Jumps: What's Going On?
ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
Stocks · News reference
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug
ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding treatment options for NMIBC and NSCLC.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.
ImmunityBio shares are trading lower after the company reported a wider GAAP net loss for the second quarter reflecting a sharp increase in expenses.
ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the